Ireland's 'rigid' approach to GDPR has negative impact on cancer trials, says report

Averil Power, CEO of the Irish Cancer Society, said: 'The solution is a national body that defines healthcare guidelines for all hospitals, and across the healthcare system.'

Ireland's restrictive interpretation of the EU's data protection laws is in “direct conflict” with the development of cancer research trials, according to a new study.

The report, released by Cancer Trials Ireland (CTI), shows that Ireland’s approach to the General Data Protection Regulation (GDPR) is overly restrictive and not in line with public opinion.